The new position of chief business officer at fast growing Scottish drug development company Haptogen has been filled with the recent appointment of Fiona Adair
Fiona Adair, who previously held business development positions at Biovation and CXR Biosciences, joins the board of Haptogen, taking responsibility for expanding the company's range of collaborations and building the product pipeline.
Haptogen CEO Jim Reid commented: "Fiona joins us at a very exciting time.
"Haptogen is unusual in that we have generated revenue from day one - not relying on external finance to grow the business.
"Our recent announcement of a major research agreement with leading Korean pharmaceutical company Daewoong illustrates the success of this approach and now Fiona will build on this base across our key therapeutic areas".
Fiona Adair added: "The company has made remarkable progress in a very short time.
"The team's unique know-how and the application of its proven technology have generated some very exciting therapeutic leads.
"I am delighted to be joining such a dynamic business.
Haptogen spun-out from the University of Aberdeen, one of the world's leading antibody engineering centres, in 2002.
The company specialises in the isolation of antibodies that recognise targets beyond the reach of other immunotechnologies.
A pioneering new approach, known as Haptomics, is generating novel therapeutic products in the areas of anti-infectives (antibiotics), CNS disease, liver disease and obesity management.
